New combo aims to control advanced colon cancer

NCT ID NCT03657641

Ongoing Disease control Sponsor: University of Southern California Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two drugs—regorafenib (a chemotherapy pill) and pembrolizumab (an immunotherapy)—in people with metastatic colorectal cancer who have already tried several other treatments. The goal is to see if the combination is safe and can slow tumor growth. About 73 participants are enrolled in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: regorafenib and pembrolizumab
What this could lead to: If it works, this combination could offer a new treatment option for patients with advanced colorectal cancer who have run out of standard therapies.
What could go wrong: This is an early-phase trial with only 73 participants, so results may not apply broadly. The combination may cause significant side effects, and it is not expected to cure the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER COLORECTAL CANCER METASTATIC

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.